{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T17:12:14Z","timestamp":1787073134991,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008276","name":"College of Medicine, University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11239-022-02696-4","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T09:04:12Z","timestamp":1662023052000},"page":"461-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease"],"prefix":"10.1007","volume":"54","author":[{"given":"Mattia","family":"Galli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Rollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latonya","family":"Been","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Zenni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8503-5736","authenticated-orcid":false,"given":"Francesco","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"issue":"22","key":"2696_CR1","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1161\/CIRCULATIONAHA.120.045465","volume":"142","author":"D Capodanno","year":"2020","unstructured":"Capodanno D, Angiolillo DJ (2020) Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes mellitus. Circulation 142(22):2172\u20132188","journal-title":"Circulation"},{"issue":"2","key":"2696_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41569-018-0080-2","volume":"16","author":"G Patti","year":"2019","unstructured":"Patti G, Cavallari I, Andreotti F, Calabr\u00f2 P, Cirillo P, Denas G et al (2019) Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol 16(2):113\u2013130","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"2696_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12265-013-9449-0","volume":"6","author":"F Rollini","year":"2013","unstructured":"Rollini F, Franchi F, Mu\u00f1iz-Lozano A, Angiolillo DJ (2013) Platelet function profiles in patients with diabetes mellitus. J Cardiovasc Transl Res 6(3):329\u2013345","journal-title":"J Cardiovasc Transl Res"},{"issue":"11","key":"2696_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1161\/CIRCULATIONAHA.116.023402","volume":"134","author":"F Franchi","year":"2016","unstructured":"Franchi F, Rollini F, Aggarwal N, Hu J, Kureti M, Durairaj A et al (2016) Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (optimizing antiplatelet therapy in diabetes mellitus)-4 study. Circulation 134(11):780\u2013792","journal-title":"Circulation"},{"issue":"10","key":"2696_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","volume":"64","author":"DJ Angiolillo","year":"2014","unstructured":"Angiolillo DJ, Jakubowski JA, Ferreiro JL, Tello-Montoliu A, Rollini F, Franchi F et al (2014) Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol 64(10):1005\u20131014","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2696_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.109.913376","volume":"123","author":"JL Ferreiro","year":"2011","unstructured":"Ferreiro JL, Angiolillo DJ (2011) Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123(7):798\u2013813","journal-title":"Circulation"},{"issue":"1","key":"2696_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12916-022-02234-2","volume":"20","author":"R Zhang","year":"2022","unstructured":"Zhang R, Mamza JB, Morris T, Godfrey G, Asselbergs FW, Denaxas S et al (2022) Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals. BMC Med 20(1):63","journal-title":"BMC Med"},{"issue":"17","key":"2696_CR8","doi-asserted-by":"publisher","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","volume":"17","author":"DJ Angiolillo","year":"2022","unstructured":"Angiolillo DJ, Galli M, Collet JP, Kastrati A, O\u2019Donghue M (2022) Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention 17(17):e1371\u2013e1396","journal-title":"EuroIntervention"},{"issue":"27","key":"2696_CR9","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","volume":"36","author":"D Aradi","year":"2015","unstructured":"Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K et al (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36(27):1762\u20131771","journal-title":"Eur Heart J"},{"issue":"16","key":"2696_CR10","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","volume":"12","author":"D Sibbing","year":"2019","unstructured":"Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L et al (2019) Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 12(16):1521\u20131537","journal-title":"JACC Cardiovasc Interv"},{"issue":"16","key":"2696_CR11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","volume":"50","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Bernardo E, Sabat\u00e9 M, Jimenez-Quevedo P, Costa MA, Palazuelos J et al (2007) Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50(16):1541\u20131547","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2696_CR12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.2337\/diabetes.55.03.06.db05-1394","volume":"55","author":"DJ Angiolillo","year":"2006","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ram\u00edrez C, Sabat\u00e9 M, Jimenez-Quevedo P et al (2006) Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55(3):780\u2013784","journal-title":"Diabetes"},{"issue":"2","key":"2696_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","volume":"142","author":"EP Navarese","year":"2020","unstructured":"Navarese EP, Khan SU, Ko\u0142odziejczak M, Kubica J, Buccheri S, Cannon CP et al (2020) Comparative efficacy and safety of oral P2Y(12) inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation 142(2):150\u2013160","journal-title":"Circulation"},{"issue":"35","key":"2696_CR14","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1093\/eurheartj\/ehv744","volume":"37","author":"F Rollini","year":"2016","unstructured":"Rollini F, Franchi F, Cho JR, DeGroat C, Bhatti M, Muniz-Lozano A et al (2016) A head-to-head pharmacodynamic comparison of prasugrel vs ticagrelor after switching from clopidogrel in patients with coronary artery disease results of a prospective randomized study. Eur Heart J 37(35):2722\u20132730","journal-title":"Eur Heart J"},{"issue":"10","key":"2696_CR15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","volume":"43","author":"M Galli","year":"2022","unstructured":"Galli M, Benenati S, Franchi F, Rollini F, Capodanno D, Biondi-Zoccai G et al (2022) Comparative effects of guided vs potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Eur Heart J 43(10):959\u2013967","journal-title":"Eur Heart J"},{"issue":"1","key":"2696_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","volume":"12","author":"F Franchi","year":"2015","unstructured":"Franchi F, Angiolillo DJ (2015) Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 12(1):30\u201347","journal-title":"Nat Rev Cardiol"},{"issue":"19","key":"2696_CR17","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jcin.2020.07.032","volume":"13","author":"G Ndrepepa","year":"2020","unstructured":"Ndrepepa G, Kastrati A, Menichelli M, Neumann FJ, W\u00f6hrle J, Bernlochner I et al (2020) Ticagrelor or prasugrel in patients with acute coronary syndromes and diabetes mellitus. JACC Cardiovasc Interv 13(19):2238\u20132247","journal-title":"JACC Cardiovasc Interv"},{"issue":"16","key":"2696_CR18","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","volume":"381","author":"S Sch\u00fcpke","year":"2019","unstructured":"Sch\u00fcpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, W\u00f6hrle J et al (2019) Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 381(16):1524\u20131534","journal-title":"N Engl J Med"},{"issue":"14","key":"2696_CR19","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","volume":"381","author":"PG Steg","year":"2019","unstructured":"Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA et al (2019) Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med 381(14):1309\u20131320","journal-title":"N Engl J Med"},{"issue":"14","key":"2696_CR20","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL et al (2021) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42(14):1289\u20131367","journal-title":"Eur Heart J"},{"issue":"20","key":"2696_CR21","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","volume":"136","author":"DJ Angiolillo","year":"2017","unstructured":"Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ et al (2017) International expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies. Circulation 136(20):1955\u20131975","journal-title":"Circulation"},{"issue":"9","key":"2696_CR22","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP et al (2020) Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation 141(9):e139\u2013e596","journal-title":"Circulation"},{"issue":"24","key":"2696_CR23","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1016\/j.jacc.2008.07.068","volume":"52","author":"D Erlinge","year":"2008","unstructured":"Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA et al (2008) Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 52(24):1968\u20131977","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2696_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011139","volume":"8","author":"F Franchi","year":"2019","unstructured":"Franchi F, James SK, Ghukasyan Lakic T, Budaj AJ, Cornel JH, Katus HA et al (2019) Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. J Am Heart Assoc 8(6):e011139","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"2696_CR25","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"SD Wiviott","year":"2008","unstructured":"Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 118(16):1626\u20131636","journal-title":"Circulation"},{"issue":"23","key":"2696_CR26","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","volume":"67","author":"DL Bhatt","year":"2016","unstructured":"Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF et al (2016) Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol 67(23):2732\u20132740","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2696_CR27","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.115.016783","volume":"133","author":"IT Meredith","year":"2016","unstructured":"Meredith IT, Tanguay JF, Kereiakes DJ, Cutlip DE, Yeh RW, Garratt KN et al (2016) Diabetes mellitus and prevention of late myocardial infarction after coronary stenting in the randomized dual antiplatelet therapy study. Circulation 133(18):1772\u20131782","journal-title":"Circulation"},{"issue":"14","key":"2696_CR28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","volume":"381","author":"PG Steg","year":"2019","unstructured":"Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA et al (2019) Ticagrelor in patients with stable coronary disease and diabetes. New Engl J Med 381(14):1309\u20131320","journal-title":"New Engl J Med"},{"issue":"5","key":"2696_CR29","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","volume":"13","author":"DJ Angiolillo","year":"2020","unstructured":"Angiolillo DJ, Capodanno D, Danchin N, Simon T, Bergmeijer TO, Ten Berg JM et al (2020) Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC Cardiovasc Interv 13(5):606\u2013617","journal-title":"JACC Cardiovasc Interv"},{"issue":"14","key":"2696_CR30","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW et al (2013) Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368(14):1303\u20131313","journal-title":"N Engl J Med"},{"issue":"4","key":"2696_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/eurheartj\/ehab876","volume":"43","author":"F Cosentino","year":"2022","unstructured":"Cosentino F, Bhatt DL, Marx N, Verma S (2022) The year in cardiovascular medicine 2021: diabetes and metabolic disorders. Eur Heart J 43(4):263\u2013270","journal-title":"Eur Heart J"},{"issue":"10283","key":"2696_CR32","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","volume":"397","author":"M Galli","year":"2021","unstructured":"Galli M, Benenati S, Capodanno D, Franchi F, Rollini F, D\u2019Amario D et al (2021) Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet 397(10283):1470\u20131483","journal-title":"Lancet"},{"issue":"21","key":"2696_CR33","first-page":"00157","volume":"S1050\u20131738","author":"M Galli","year":"2021","unstructured":"Galli M, Franchi F, Rollini F, Angiolillo DJ (2021) Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. Trends Cardiovasc Med S1050\u20131738(21):00157\u201300162","journal-title":"Trends Cardiovasc Med"},{"issue":"2","key":"2696_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11239-012-0846-z","volume":"35","author":"JL Ferreiro","year":"2013","unstructured":"Ferreiro JL, Ueno M, Tello-Montoliu A, Tomasello SD, Capodanno D, Capranzano P et al (2013) Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. J Thromb Thrombolysis 35(2):155\u2013164","journal-title":"J Thromb Thrombolysis"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-022-02696-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-022-02696-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-022-02696-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T05:08:59Z","timestamp":1665464939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-022-02696-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["2696"],"URL":"https:\/\/doi.org\/10.1007\/s11239-022-02696-4","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"13 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.G. declares that he has received honoraria from Terumo. F.F. declares that he has received payment as an individual for consulting fee or honorarium from AstraZeneca, Bayer and Sanofi. Institutional payments for grants from PLx Pharma, and The Scott R. MacKenzie Foundation. F.R. declares that he has received honoraria from Chiesi. D.J.A. declares that he has received consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, and Sanofi,. D.J.A. also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions and Scott R. MacKenzie Foundation. The remaining authors report no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}